Galapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026 Mechelen, Belgium

Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026

Belgium; April 28, 2026, 22:01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at

the Company's Annual and Extraordinary Shareholders' Meetings (AGM and EGM) held on 28 April 2026 were approved.

The AGM approved, amongst other items:

The EGM approved, amongst other items:

All documents related to the AGM and EGM can

be consulted on our website. The minutes of the meetings will be made available in due course.

"I am grateful for our shareholder support

as we execute our transformation. I would also like to sincerely thank J r me for his leadership throughout this transformative

period for Galapagos. His guidance and steadfast support through the strategic review and implementation of the Company's reinvention

have been instrumental in positioning Galapagos for its next phase of growth and value creation. He has been a great partner and provided

valuable insights," said Henry Gosebruch, Chief Executive Officer of Galapagos.

Gosebruch continued, "We are delighted to

welcome Gino to our Board of Directors as our next Chair. His extensive operational, strategic and business development expertise shaped

by global leadership in our sector will be invaluable as we execute on our strategy to deliver meaningful patient impact and sustainable

shareholder returns."

Galapagos is a biotechnology company built to

bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal

making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients

and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Galapagos prioritizes oncology and

immunology & inflammation programs with clear clinical proof-of-concept in emerging areas. For more information, visit www.glpg.com or

For further information, contact Galapagos:

Forward-looking statements

This release may contain

forward-looking statements. Such forward-looking statements are not guarantees of future results. These statements speak only as of the

date of publication of this release. We expressly disclaim any obligation to update any forward-looking statements in this release, unless

specifically required by law or regulation.

contents of our website, including the annual report for the financial year 2025 and the report prepared by the Board of Directors at

the occasion of the Extraordinary Shareholders' Meeting, and any other website that may be accessed from our website, shall not

be deemed incorporated by reference in any filing under the Securities Act of 1933.